Abstract LB-B33: Nonclinical safety evaluation of two distinct second generation variants of anti-CTLA4 monoclonal antibody, ipilimumab, in monkeys
Karen Price(Purchase College), Michael J. Graziano(The Bristol-Myers Squibb Children's Hospital), Helen G. Haggerty(Bristol-Myers Squibb (Germany)), James H. Crona(The Bristol-Myers Squibb Children's Hospital), Wendy Freebern(Bristol-Myers Squibb (Germany)), Austin Thekkumthala(The Bristol-Myers Squibb Children's Hospital), Frank Simutis(The Bristol-Myers Squibb Children's Hospital), Daniel Szatkowski(The Bristol-Myers Squibb Children's Hospital), Rima Srour(The Bristol-Myers Squibb Children's Hospital), Jean G. Sathish(Pfizer (United States)), John Engelhardt(Bristol-Myers Squibb (United States)), Jennifer Wheeler(Population Services International), Bojing Wang(The Bristol-Myers Squibb Children's Hospital), Courtni Newsome(The Bristol-Myers Squibb Children's Hospital), Todd Bunch(The Bristol-Myers Squibb Children's Hospital), Anthony M. Fletcher(The Bristol-Myers Squibb Children's Hospital), John Kozlosky(The Bristol-Myers Squibb Children's Hospital), Lila Ramaiah(The Bristol-Myers Squibb Children's Hospital), Annette Capozzi(The Bristol-Myers Squibb Children's Hospital)
Cited by 11
Related Papers
Rational Development of LEA29Y (belatacept), a High-Affinity Variant of CTLA4-Ig with Potent Immunosuppressive Properties
|American Journal of Transplantation|2005|714
Cancer Drug Discovery and Development
|Humana Press eBooks|2003|194
Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival
|The Journal of Immunology|2005|183
A conserved intratumoral regulatory T cell signature identifies 4-1BB as a pan-cancer target
|Journal of Clinical Investigation|2020|133
Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection
|American Journal of Transplantation|2017|96